Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia

被引：0
|
作者：
Enriqueta Albizua
Miguel Gallardo
Santiago Barrio
Inmaculada Rapado
Ana Jimenez
Rosa Ayala
Daniel Rueda
Beatriz Sanchez-Espiridion
Eulalia Puigdecanet
Blanca Espinet
Lourdes Florensa
Carles Besses
Joaquin Martinez-Lopez
机构：
[1] Hospital Universitario 12 de Octubre,Servicio de Hematología
[2] Servicio de Hematología,Laboratoris de Citologia Hematológica/Citogenética Molecular. Servei de Patologia, GRETNHE
[3] Hospital Virgen de la Salud,Servicio de Hematología
[4] Spanish National Cancer Research Centre (CNIO),undefined
[5] IMIM-Hospital del Mar,undefined
[6] IMIM-Hospital del Mar,undefined
来源：
Annals of Hematology | 2011年 / 90卷
关键词：
Polycythemia vera; Essential thrombocythemia; Gene expression profile; RT-PCR; Response to hydroxyurea; Src family kinase (SFK);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This study investigates the differential gene expression profile of JAK2V617F-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2V617F-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
引用
收藏
页码：939 / 946
页数：7
相关论文
共 50 条
  • [21] Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses
    Tsewang Tashi
    Sabina Swierczek
    Soo Jin Kim
    Mohamed E. Salama
    Jihyun Song
    Nahla Heikal
    Katherine Y. King
    Kim Hickman
    Scott Litton
    Josef T. Prchal
    Leukemia, 2018, 32 : 1830 - 1833
  • [22] Leukocyte alkaline phosphatase expression predicts the JAK2 V617F mutation status in polycythemia vera and essential thrombocythemia
    Rambaldi, A.
    Guerini, V.
    Carobbio, A.
    Salvi, A.
    Spinelli, O.
    Delaini, F.
    Finazzi, G.
    Barbui, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 414 - 415
  • [23] Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings
    Ferdowsi, S.
    Atarodi, K.
    Amirizadeh, N.
    Toogeh, G.
    Azarkeivan, A.
    Shirkoohi, R.
    Faranoush, M.
    Vaezi, M.
    Alimoghaddam, K.
    Ghavamzadeh, A.
    Naghadeh, H. Teimori
    Ghaffari, S. H.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (05) : 661 - 667
  • [24] JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
    Panova-Noeva, Marina
    Marchetti, Marina
    Buoro, Sabrina
    Russo, Laura
    Leuzzi, Annamaria
    Finazzi, Guido
    Rambaldi, Alessandro
    Ottomano, Cosimo
    ten Cate, Hugo
    Falanga, Anna
    BLOOD, 2011, 118 (09) : 2599 - 2601
  • [25] MicroRNA Expression and JAK2 Allele Burden in Bone Marrow Trephine Biopsies of Polycythemia Vera, Essential Thrombocythemia and Early Primary Myelofibrosis
    Gebauer, Niklas
    Bernard, Veronica
    Gebauer, Wolfgang
    Feller, Alfred C.
    Merz, Hartmut
    ACTA HAEMATOLOGICA, 2013, 129 (04) : 251 - 256
  • [26] Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation
    Hattori, Norimichi
    Fukuchi, Kunihiko
    Nakashima, Hidetoshi
    Maeda, Takashi
    Adachi, Daisuke
    Saito, Bungo
    Yanagisawa, Kouji
    Matsuda, Isao
    Nakamaki, Tsuyoshi
    Gomi, Kunihide
    Tomoyasu, Shigeru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) : 181 - 188
  • [27] Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation
    Norimichi Hattori
    Kunihiko Fukuchi
    Hidetoshi Nakashima
    Takashi Maeda
    Daisuke Adachi
    Bungo Saito
    Kouji Yanagisawa
    Isao Matsuda
    Tsuyoshi Nakamaki
    Kunihide Gomi
    Shigeru Tomoyasu
    International Journal of Hematology, 2008, 88 : 181 - 188
  • [28] A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter
    Levy, Richard
    Bradley, Edward C.
    Schacter, Lee
    Garrett, William M.
    Vaddi, Kris
    Contel, Nancy
    Rumi, Elisa
    Gattoni, Elisabetta
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro
    BLOOD, 2009, 114 (22) : 132 - 132
  • [29] JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
    Reis Monte-Mor, Barbara da Costa
    da Cunha, Anderson Ferreira
    Barbosa Pagnano, Katia Borgia
    Saad, Sara Terezinha
    Lorand-Metze, Irene
    Costa, Fernando Ferreira
    GENETICS AND MOLECULAR BIOLOGY, 2007, 30 (02) : 336 - 338
  • [30] CLONAL DYNAMICS OF JAK2V617F AND NON-DRIVER MUTATIONS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ON HYDROXYUREA TREATMENT
    Lierni, Fernandez-Ibarrondo
    Joan, Gibert
    Concepcion, Fernandez-Rodriguez
    Laura, Camacho
    Anna, Angona
    Marcio, Andrade
    Nieves, Garcia-Gisbert
    Leonor, Arenillas
    Raquel, Longaron
    Francesc, Garcia-Pallarols
    Antonio, Salar
    Carles, Besses
    Beatriz, Bellosillo
    HAEMATOLOGICA, 2021, 106 (10) : 122 - 123
12345